William Blair & Company
ACHN

William Blair & Company’s Achillion Pharmaceuticals ACHN Stock Holding History

William Blair & Company’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,000
Closed -$61K – 2221
2014
Q4 		$61K Hold
5,000
– – ﹤0.01% 2041
2014
Q3 		$49K Buy
+5,000
New +$46.4K ﹤0.01% 2052

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company's ACHN Position: Q4 2019 in Review

William Blair & Company sold out of Achillion Pharmaceuticals (ACHN) in Q4 2019, closing a stake of 37,000 shares — an estimated $133K sold.

William Blair & Company first reported a position in ACHN in Q2 2013 and held it in 25 quarters. The position peaked at $1.31M in Q2 2015. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • William Blair & Company reported no remaining Achillion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • William Blair & Company sold 37,000 Achillion Pharmaceuticals shares in Q4 2019, an estimated $133K.
  • William Blair & Company first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • William Blair & Company's Achillion Pharmaceuticals position peaked at $1.31M in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on William Blair & Company's 13F filing for Q4 2019, filed 13 Feb 2020.